Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
There is encouraging news from Cedars-Sinai Medical Group - 50% of patients participating in an experimental treatment for aggressive brain tumors have survived longer than 5 years since diagnosis.
Presenting their findings at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco this month, the researchers reported eight of the original 16 participants in the study had defied the odds by surviving 5 years.
The original trial was testing a new immune system therapy against the most malignant form of tumor - glioblastoma multiforme.
According to the American Brain Tumor Association (ABTA), glioblastomas are particularly troublesome as the cells can reproduce quickly and are supported by a large network of blood vessels.
ABTA estimates that 17% of all primary brain tumors are glioblastomas and notes that their frequency increases with age, affecting more men than women.
The Cedars-Sinai study participants signed up for a new trial testing the safety of the ICT-107 vaccine, which alerts the immune system to the presence of cancer cells and triggers a tumor-killing response. The vaccine targets six antigens involved in the development of the cancer cells.
After receiving conventional treatment for the tumor - surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy - study participants also received a vaccine three times at 2-week intervals after radiation and chemotherapy.
According to the information presented at the meeting, seven of the original participants are still living, with length of survival ranging from 60.7 to 82.7 months after diagnosis.
Six of the patients were also "progression-free" for more than 5 years, meaning the tumors did not return or need more treatment during that time.
Four participants still remain free of disease with good quality of life at lengths ranging from 65.1 to 82.7 months following diagnosis. One patient who remained free of brain cancer for 5 years died of leukemia.
The researchers explained that the study showed median overall survival of 38.4 months. Typically, when tumor-removal surgery is followed by standard care, median length of survival is about 15 months.
Median progression-free survival - the time from treatment to tumor recurrence - was 16.9 months at study's end. With standard care, the median is about 7 months.
The Cedars-Sinai team explained that all eight long-term survivors had tumors with at least five antigens, 75% had tumors with all six, and 100% had tumors with at least four antigens associated with cancer stem cells - cancer-originating cells that appear to help tumors resist radiation and chemotherapy, and even regenerate after treatment.
Dr. Surasak Phuphanich, director of the Neuro-Oncology Progam at the Cochran Brain Tumor Center, says:
"Our findings suggest that targeting antigens that are highly expressed by cancer stem cells may be a viable strategy for treating patients who have glioblastomas. Long-term remission of disease in this group of patients was correlated with the expression of cancer stem cell tumor-associated antigens."
The vaccine is tailor-made for each patient using dendritic cells taken from their own white blood cells. Dendritic cells are one of the immune system's most powerful antigen-presenting cells - cells that enable the immune system to identify invaders.
Researchers grow the dendritic cells in a laboratory with synthetic peptides of the six target antigens - essentially training the cells recognize these antigens as invaders. These new cells are then re-introduced to the patient, where they will hunt down and destroy any lingering tumor cells.
Based on the success of the trial so far, the ICT-107 vaccine has entered Phase II testing with a multicenter, randomized placebo-controlled trial that began in 2011.
Written by Belinda Weber
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Update: 50 Percent of Patients in Cedars-Sinai Brain Cancer Study Alive After Five Years, News release Accessed 25 November 2013.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Weber, Belinda. "Vaccine promises longer survival for brain tumor patients." Medical News Today. MediLexicon, Intl., 26 Nov. 2013. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/articles/269321>
Weber, B. (2013, November 26). "Vaccine promises longer survival for brain tumor patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/269321.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.